- Home
- AUST vs COCP Comparison
AUST vs COCP Comparison
Compare AUST & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- COCP
- Stock Information
- Founded
- AUST 2020
- COCP 2006
- Country
- AUST Canada
- COCP United States
- Employees
- AUST N/A
- COCP 11
- Industry
- AUST
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- COCP Health Care
- Exchange
- AUST Nasdaq
- COCP Nasdaq
- Market Cap
- AUST 19.0M
- COCP 15.4M
- IPO Year
- AUST 2022
- COCP N/A
- Fundamental
- Price
- AUST $1.37
- COCP $1.80
- Analyst Decision
- AUST
- COCP Strong Buy
- Analyst Count
- AUST 0
- COCP 1
- Target Price
- AUST N/A
- COCP $6.00
- AVG Volume (30 Days)
- AUST 53.3K
- COCP 22.5K
- Earning Date
- AUST 08-06-2025
- COCP 08-13-2025
- Dividend Yield
- AUST N/A
- COCP N/A
- EPS Growth
- AUST N/A
- COCP N/A
- EPS
- AUST N/A
- COCP N/A
- Revenue
- AUST N/A
- COCP N/A
- Revenue This Year
- AUST N/A
- COCP N/A
- Revenue Next Year
- AUST N/A
- COCP N/A
- P/E Ratio
- AUST N/A
- COCP N/A
- Revenue Growth
- AUST N/A
- COCP N/A
- 52 Week Low
- AUST $0.80
- COCP $1.12
- 52 Week High
- AUST $3.19
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- AUST 52.55
- COCP 69.71
- Support Level
- AUST $1.32
- COCP $1.46
- Resistance Level
- AUST $1.45
- COCP $1.60
- Average True Range (ATR)
- AUST 0.08
- COCP 0.08
- MACD
- AUST -0.00
- COCP 0.02
- Stochastic Oscillator
- AUST 67.86
- COCP 92.31
About AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).